Introduction
Use of multi-agent chemotherapy alone or in combination with radiation therapy (XRT) cures more than 80% of patients with Hodgkin's lymphoma (HL). 1 High-dose chemotherapy and autologous SCT (HDC ASCT) is wellaccepted therapy for most patients with HL, who have persistent disease or relapse after multi-agent chemotherapy/ combination treatment. HDC ASCT has shown superior event-free survival (EFS) when compared with salvage chemotherapy alone ( Figure 1 ). 2, 3 Most studies reported relapsed and refractory HL as a single group. Patients with primary refractory HL (PR-HL), who received salvage chemotherapy had an extremely poor outcome. 4, 5 The outcome of HDC ASCT in PR-HL is not as encouraging as in relapsed HL.
Unlike relapsed HL, PR-HL patients undergo considerable selection and significant portion of patients do not receive HDC ASCT because of progressive disease (PD) while on salvage chemotherapy, poor performance status and older age.
We retrospectively analyzed our patients who underwent HDC ASCT for PR-HL.
Patients and methods

Study design and patients selection
This is a retrospective cohort analysis. Study design and data collection forms were approved by the Institutional Research Advisory Counsel. All patients and/or their parents provided written informed consent for salvage chemotherapy, related procedures and HDC ASCT as per institutional guidelines. All patients with relapsed or PR-HL who had HDC ASCT were identified from Oncology Data Unit. From 1996 to May 2006, 113 consecutive patients with biopsy-proven HL underwent HDC ASCT. Of these, 66 had PR-HL. All patients' paper and electronic charts were retrospectively reviewed to collect required data. Before HDC ASCT, all patients were required to have adequate hematological, renal, hepatic, pulmonary and cardiac functions.
Definitions
All patients were staged according to the Ann Arbour staging system. Bulky disease is defined as mediastinal mass greater than or equal to one-third of the maximum thoracic wall diameter or any mass equal to or greater than 8 cm. Complete response (CR) was defined as disappearance of all lymphoma-related abnormalities; partial response (PR), more than 50% reduction; no response or stable disease (NR/SD) as less than PR; progression as appearance of any new lesion or more than 25% increase in the presence of previous lesion or appearance of disease-related symptoms. PR-HL is defined as PR, NR/SD or PD after planned multi-agent chemotherapy with or without XRT or relapsing within 3 months of finishing the planned treatment after achieving a CR or CR unconfirmed (CRu), commonly referred as short-lived CR.
Response evaluation
Patients on primary chemotherapy (ABVD, CHOP and others) had response evaluation (both clinical and radiological) in the middle and at the end of planned initial treatment. After starting salvage chemotherapy, all patients had response evaluation after 2-3 cycles of salvage chemotherapy.
Prognostic factors evaluation
Data were collected both at the time of diagnosis and before the initiation of salvage chemotherapy (after induction failure). This included age at HDC ASCT up to 21 years or older, presence of B symptoms, prior XRT, presence or absence of short-lived CR/CRu (relapsing within 3 months of CR or CRu), bulky disease, mediastinal, spleen and extranodal involvement, HL International Prognostic Scoring System (IPI) good vs bad group (0, 1 and 2 factors as good and X3 as bad group) and lactate dehydrogenase (LDH). Response to salvage chemotherapy was also evaluated. relapse or progression after HDC ASCT had appropriate restaging work-up as required.
Salvage chemotherapy
Statistical analysis SPSS Version 14 was used for statistical analyses. Survival analyses were performed using the Kaplan -Meier method and compared using the log-rank test (Figure 2 ). OS was calculated both from the diagnosis and from the date of ASCT. Event is defined as presence of disease after HDC ASCT, death due to any cause or relapse after HDC ASCT. EFS is calculated from the date of stem cell infusion. The impact of the following prognostic factors (at the time of relapse or progression before the start of salvage chemotherapy) was evaluated using one-way analyses of variance (ANOVA) and multivariate regression analysis for OS and EFS as the dependent variable: age at ASCT up to 21 vs 421, B symptoms, prior XRT, relapsed vs refractory disease, bulky disease, mediastinal involvement, spleen involvement, extranodal involvement, HL IPI good (0, 1 and 2) vs bad (X3), elevated LDH and response to salvage chemotherapy. Results were considered significant if Po0.05 (two-sided). Response to salvage chemotherapy was separately analyzed as an additional factor (CR/CRu vs PR/NR/SD) among all the factors mentioned above and reported separately.
Results
Tissue reconfirmation, patient selection and salvage chemotherapy Sixty-six (66) patients with PR-HL were identified. Of these, 38 (58%) had biopsy-proven reconfirmation of disease at the time of relapse/progression. Other patients had unequivocal evidence of PR-HL based on clinical and radiological evaluation. Excluding those 26 patients who relapsed within 3 months and 9 patients who had NR/SD or PD, 31 patients with PR after initial induction therapy underwent HDC and ASCT. Of these 31 patients at the time of evaluation before the initiation of salvage chemotherapy, 17 had stage IV disease with extranodal involvement (lung involvement 12 patients, liver in 5 patients and bone marrow in 4 patients). Four of these 17 patients also had prior XRT. One patient had bulky disease with chest wall invasion. In the remaining 13 patients, 2 had prior XRT, 4 had stage III disease and 3 of them had spleen involvement, 3 had bulky disease and 1 of them had prior XRT. Other patients had sizable disease or had advanced stage at presentation with persistent disease before salvage chemotherapy.
ESHAP was the primary salvage chemotherapy used in our institution. Patient characteristics and different prognostic factors are shown in Tables 1 and 2 , respectively. Sixty (92%) of these patients had ESHAP as a second-line chemotherapy (first-line salvage, Table 1 ). One patient received ESHAP as second-line salvage after failing ABVD and then COPP. One patient after failing COPP/ ABVD þ XRT, relapsed within 3 months, again received localized radiation, relapsed again within 3 months and received ESHAP alternating with IMCCNU. Two patients had ESHAP and ESHAP þ XRT after failing ABVD; they initially refused HDC ASCT but relapsed within 3 months of finishing ESHAP and then received IMVP-16 as secondline salvage chemotherapy followed by HDC ASCT.
Stem cell mobilization
Fifty-seven patients (86%) had ESHAP þ G-CSF as the mobilization regimen. Five patients (8%) were mobilized Primary refractory Hodgkin's lymphoma and autologous SCT S Akhtar et al with cytoxan and G-CSF and four patients (6%) had IMVP-16 þ G-CSF as mobilization regimen. Source of stem cell was peripheral blood stem cells in 63 patients, bone marrow harvest þ peripheral blood in two and bone marrow harvest in one.
Response to ESHAP/salvage Patients who had PD were not eligible for HDC ASCT. Patients with stable or responsive disease received HDC ASCT. These results are shown in Table 3 . Before HDC ASCT, 13 patients (20%) were in CR/CRu, 42 (64%) had PR and 11 (17%) had NR or SD.
Post-HDC ASCT evaluation
Excluding one patient who died on day þ 6, neutrophil engraftment was 100% but two patients failed platelet engraftment by day 28. Both these patients were heavily pretreated, one had COPP/ABVD total of eight cycles followed by ESHAP alternating with IMCCNU seven cycles and the other one had MOPP Â 6 followed by ABVD Â 6 then XRT and finally ESHAP alternating with IMCCNU six cycles. Both these patients were treated in 1995-1996. Post-HDC ASCT evaluation results are shown in Table 3 . Thirty-five patients (53%) were in CR (12 of these patients were already in CR/CRu after salvage chemotherapy). Fourteen (21%) achieved PR and 3 (5%) had NR/SD after salvage chemotherapy. Ten patients (15%) had PD before or at the time of first post-transplant evaluation around day 100.
Four patients with PR after HDC ASCT and one with PD achieved CR after XRT. One patient who had persistent localized inguinal area disease, even after radiation therapy post-HDC ASCT, had surgical resection and is disease-free (14 months follow-up after surgery). One patient who had localized relapse after HDC ASCT also achieved CR after XRT. All these patients are in continuous CR (CCR). Out of 53 patients, 24 (45%) with PR/NR/SD after salvage chemotherapy achieved CR after HDC ASCT (13, that is 20%, patients were in CR after ESHAP). Combining all the CR/CRu/CCR and also CR that resulted from XRT post-HDC ASCT or surgical resection in one case, a total of 43 patients (65%) achieved CR.
Follow-up and survival analysis Details are provided in Table 3 . Eight surviving patients (12%) had o12 months follow-up; median follow-up from diagnosis is 38.5 months and from HDC and ASCT is 22.8 months. Median OS from diagnosis is 78 months and from HDC ASCT 57 months.
At the time of current evaluation on 1 March 2007 (Table 3) , 13 (20% of 66 patients and 30% of 43 who achieved CR) had relapsed. Thirty-one patients (47%) are still in CCR. Twenty-two patients (33%) died due to disease and 11 (17%) are alive with disease. Forty-two patients (64%) had an event and EFS is only 36%. OS is 64%, although the follow-up is relatively short. Median OS has not reached yet. Two patients had treatment-related mortality. One female patient, 31 years old, died on day þ 6 due to diffuse pulmonary hemorrhage; she had PR after salvage chemotherapy. The other 22-year-old female patient developed post-HDC ASCT biopsy-proven diffuse interstitial pneumonitis with diffuse alveolar damage and died 3 months after transplant. She was in CR after salvage chemotherapy.
Impact of prognostic factors on EFS and OS
We also thoroughly reviewed multiple prognostic factors ( Table 2 ). The effect of all these factors at the time of relapse/progression (before the initiation of salvage ESHAP chemotherapy) on EFS and OS with multivariate analysis are shown in Table 5 ). Many of them are too small for a meaningful outcome analysis. Most studies do not report the total number of PR-HL patients who started out for HDC ASCT. There is no common definition for PR-HL. Some studies selected patients the way we did 6-10 but some used even more strict criteria [11] [12] [13] [14] [15] that is patients with disease progression while on chemotherapy or progression within 3 months after PR. There is no study to compare patients with disease progression while on chemotherapy vs those relapsing within 3 months of achieving CR or CRu.
Comparison of patients with PR-HL who had HDC ASCT with other treatment modality like salvage chemotherapy or radical XRT is limited to few randomized trials 2,3 and mainly nonrandomized reports or subset analysis. 7, 8, 12, 16, 17 These reports have varying results anywhere from as good as HDC ASCT (for EFS) to worse than HDC ASCT. One of the randomized trials failed to accrue patients and was closed prematurely as patients refused to be randomized to salvage chemotherapy-only arm, given the encouraging results in favor of EFS. 2 It is also difficult to compare salvage chemotherapy alone vs HDC ASCT as most patients who have chemosensitive disease to salvage chemotherapy usually proceed to HDC ASCT and those who are progressing are not usually offered HDC ASCT. 8 Josting et al.
8 reported large percentage of the patients on salvage had PD on salvage (60%), severe toxicity (11%) and were excluded from HDC ASCT program. Morabito et al. 17 also reported that 29% patients were not candidates for curative intent therapy. In his analysis, HDC ASCT clearly showed survival benefit over conventional dose salvage chemotherapy, 4-year OS 81 vs 38%. Some other studies had also reported superior EFS favoring HDC ASCT over salvage chemotherapy alone. 7, 12, 16 There are major differences between our report and previously reported data. Our data are from a large single institution report of the outcome of PR-HL. Our data are different from many published studies as we have younger patients, minimal pretreatment, offered early HDC ASCT, reporting only HL, exclusively used ESHAP as salvage, high percentage of tissue reconfirmation at progression and had uniform guidelines for all patients. Our results are same as any other report; main limitation is relatively short follow-up.
We thoroughly reviewed the impact of prognostic factors in this group of patients and identified elevated LDH and mediastinal involvement as negative prognostic factors. EFS with elevated LDH vs normal LDH (Fisher's exact test) was 19 vs 42% (P ¼ 0.09), respectively and on multivariate analysis P ¼ 0.041. Mortality with mediastinal involvement vs no involvement (Fisher's exact test) was 44 vs 12.5% (P ¼ 0.02), respectively and on multivariate Table 5 .
In patients with PR-HL, ESHAP þ BEAM combination þ /ÀXRT resulted in 76% response and 65% CR rate. Despite this high responsiveness, 30% of patients with CR relapsed. In all, 33% patients had died after HDC ASCT. For EFS, elevated LDH and for OS, mediastinal involvement is a negative prognostic factor. At a median follow-up of 22.8 months from HDC ASCT, EFS is only 36%. Our results are comparable with other reports. Main limitation is relatively short follow-up. Despite these results, HDC ASCT is considered standard option for this group. Better treatment strategies are urgently required for this group of patient population.
